Elsevier

JACC: Heart Failure

Volume 7, Issue 11, November 2019, Pages 922-932
JACC: Heart Failure

Focus Issue: Developing Therapies in Heart Failure: A New Era for Drugs and Devices
State-of-the-Art Review
The Future of Wearables in Heart Failure Patients

https://doi.org/10.1016/j.jchf.2019.08.008Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Wearable health devices are one component of digital and mobile health that have the potential to improve heart failure care and outcomes.

  • Current data for heart failure wearables are limited to observational studies and small, randomized controlled trials.

  • Wearables are being incorporated into heart failure clinical trials as part of interventions and outcome assessments.

  • The key value proposition of wearables is to extend data collection on patients outside of conventional clinical encounters.

Abstract

The adoption of mobile health (mHealth) devices is creating a unique opportunity to improve heart failure (HF) care. The rise of mHealth is driven by multiple factors including consumerism, policy changes in health care, and innovations in technology. Wearable health devices are one aspect of mHealth that may improve the delivery of HF care by allowing for medical data collection outside of a clinician’s office or hospital. Wearable devices are externally applied and capture functional or physiological data in order to monitor and improve patients’ health. Most wearable sensors capture data continuously and may be incorporated into accessories (e.g., a watch or clothing) or may be applied as a cutaneous patch. Wearable devices are often paired with another device, such as a smartphone, to collect, interpret, or transmit data. This study assessed the potential applications of wearable devices in HF care, summarizes available data for wearables, and discusses the future of wearables for improving the health of patients with HF.

Key Words

biosensors
heart failure
wearable electronic devices

Abbreviations and Acronyms

ADHF
acute decompensated heart failure
AF
atrial fibrillation
ECG
electrocardiogram
HF
heart failure
mHealth
mobile health
ReDS
remote dielectric sensing

Cited by (0)

Supported by the Duke Clinical Research Institute, Durham, North Carolina. Dr. DeVore has received research support from AstraZeneca, Amgen, American Heart Association, Bayer, Luitpold Pharmaceuticals, Medtronic, National Heart, Lung, and Blood Institute, Patient-Centered Outcomes Research Institute, and Novartis; and is a consultant for AstraZeneca, LivaNova, Mardil Medical, Novartis, and Procyrion. Dr. Hernandez has received research support from Regent, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Verily; and is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Merck, and Novartis. Dr. Wosik has reported that he has no relationships relevant to the contents of this paper to disclose.